This product comprises a CRISPR/Cas9-edited polyclonal knockout cell population targeting the ALDH1B1 gene in the human KYSE-30 esophageal squamous cell carcinoma host line. The polyclonal format provides a heterogeneous pool of cells bearing distinct loss-of-function mutations at the target locus, offering a robust model to interrogate ALDH1B1-dependent phenotypes without clonal biases. The knockout cell population is generated via non-homologous end joining (NHEJ)-mediated disruption of the ALDH1B1 coding region, enabling broad functional ablation across the cell pool. Researchers are supplied with viable, early-passage cells suitable for direct expansion in culture, enabling immediate deployment in downstream functional assays. All lots are verified by genomic PCR and Sanger sequencing to confirm target locus editing, with recommended validation of protein-level knockout through immunoblotting or quantitative RT-qPCR prior to experimentation.
Established from a well-differentiated human esophageal squamous cell carcinoma, the KYSE-30 cell line is a widely employed model in esophageal cancer biology. Derived from a primary tumor resection, KYSE-30 cells exhibit epithelial morphology and retain hallmark features of squamous cell carcinoma, including robust proliferative capacity and tumorigenicity in xenotransplantation. The cell line expresses key markers of the esophageal epithelial lineage and has been extensively utilized to study oncogenic signaling, drug resistance, and cancer stem cell properties. KYSE-30 cells harbor genetic alterations consistent with esophageal squamous cell carcinoma, including TP53 mutations and dysregulated Wnt/??-catenin pathway activity, rendering them particularly relevant for investigating the interplay between ALDH1B1-mediated retinoic acid signaling and malignant progression. The host background provides a clinically pertinent context for assessing how loss of aldehyde dehydrogenase activity impacts cancer cell behavior and therapeutic sensitivity.
ALDH1B1 encodes a mitochondrial aldehyde dehydrogenase that catalyzes the irreversible oxidation of short- and medium-chain aldehydes using NAD+ as a cofactor. Among its substrates, ALDH1B1 preferentially converts retinaldehyde to all-trans-retinoic acid, a critical morphogen that activates nuclear retinoic acid receptors (RAR?? and RXR??) to drive transcriptional programs controlling differentiation, proliferation, and stem cell maintenance. ALDH1B1 functions downstream of retinol metabolism and interacts directly with NAD+ and retinaldehyde, potentially forming heterotetramers with other ALDH family members to modulate substrate specificity. The gene is transcriptionally regulated by upstream factors including Wnt/??-catenin pathway effectors, C/EBP??, and retinoic acid receptors themselves, establishing a feedback loop. Downstream targets encompass retinoic acid-responsive genes such as HOX gene clusters and CYP26A1, the latter encoding a cytochrome P450 that degrades retinoic acid, thereby fine-tuning signaling output. Disruption of ALDH1B1 abolishes retinaldehyde-to-retinoic acid conversion, leading to diminished RAR??/RXR?? transcriptional activity and altered expression of target genes, while also compromising cellular aldehyde detoxification capacity.
In the context of esophageal squamous cell carcinoma, ALDH1B1 appears critical for maintaining cancer stem cell phenotypes and protecting against aldehyde-induced stress. KYSE-30 cells possess endogenous ALDH enzymatic activity, as measurable by ALDEFLUOR assay, and the polyclonal knockout population serves to dissect the contribution of ALDH1B1 specifically. Ablation of ALDH1B1 is predicted to impair retinoic acid supply, thereby attenuating signaling through RAR??/RXR?? and reducing transcription of stem cell maintenance programs, potentially sensitizing cells to differentiation cues. Concurrently, loss of aldehyde detoxification capacity may elevate intracellular levels of reactive aldehydes, enforcing oxidative stress and DNA damage. This positions the knockout model to directly assess how ALDH1B1 influences chemoresistance, migration, and clonogenic growth in esophageal carcinoma. By comparing polyclonal knockout cells to wild-type KYSE-30 or vector-control pools, researchers can systematically evaluate ALDH1B1-dependent vulnerabilities and biomarker signatures.
The ALDH1B1 knockout KYSE-30 polyclonal cell population is ideally suited for a diversity of experimental applications aimed at deciphering retinoic acid signaling and aldehyde detoxification in esophageal cancer. Functional assays such as ALDEFLUOR staining can validate reduced aldehyde dehydrogenase activity, while retinoic acid quantification via LC-MS/MS confirms metabolic disruption. Combining this model with Western blotting and RT-qPCR enables probing of downstream target expression, including HOX gene clusters and CYP26A1, following RAR??/RXR?? agonist or antagonist treatment. Cell proliferation, migration, and drug sensitivity screens??especially against chemotherapeutics like cisplatin or 5-fluorouracil??can uncover ALDH1B1-dependent resistance mechanisms. Furthermore, sphere formation or limiting dilution assays address stem cell frequency alterations. Researchers pursuing these or related studies are encouraged to contact Ascent Research for technical support and product information.
